Phelan-McDermid syndrome (also known as 22q13 deletion syndrome) is a syndromic form of autism spectrum disorder and currently thought to be caused by heterozygous loss of SHANK3. However, patients most frequently present with large chromosomal deletions affecting several additional genes. We used human pluripotent stem cell technology and genome editing to further dissect molecular and cellular mechanisms. We found that loss of JIP2 (MAPK8IP2) may contribute to a distinct neurodevelopmental phenotype in neural progenitors (NPCs) affecting neuronal maturation. This is most likely due to simultaneous misregulation of JNK proteins, leading to impaired generation of mature neurons. Furthermore, semaphorin signaling is compromised in patient NPCs and neurons. Pharmacological stimulation of neuropilin receptor 1 (NRP1) rescued impaired semaphorin pathway activity and JNK expression in patient neurons. Our results suggest a novel disease-specific mechanism involving the JIP/JNK complex and identify NRP1 as potential therapeutic target.
Introduction
22q13 Deletion Syndrome (22qDS) is commonly caused by deletions in the qterminal end of chromosome 22. Characteristic symptoms of 22qDS include developmental delay, intellectual disability and severe delay or complete absence of speech (Phelan, 2008) . 22qDS is currently seen as synaptopathy, predominantly caused by heterozygous deletion of the gene SHANK3. The importance of SHANK3 protein for functional synapses has been robustly established (Durand et al., 2007; Jiang and Ehlers, 2013; Mei et al., 2016; Peça et al., 2011; Uchino and Waga, 2013) . Very recently SHANK3 has been functionally implicated in subcellular signaling pathways, such as the mTORpathway, and it has been shown that SHANK3 depletion impairs intracellular signaling (Bidinosti et al., 2016; Shcheglovitov et al., 2013) .
However, the contribution of additional, concomitantly deleted genes in this disease is largely unknown. The vast majority of patients nonetheless present with highly variable chromosomal deletions that can effect several genes located up or downstream of SHANK3 (Bonaglia et al., 2011; Sarasua et al., 2014) . One interesting candidate gene commonly co-deleted in 22qDS is MAPK8IP2 (aka JIP2). JIP2 is know to be a crucial scaffolding protein that facilitates the activities of MAP kinase pathway proteins including MEKs, ERKs and JNKs (Whitmarsh, 2006) . Regulated activation of the MAPK pathway, and in particular correct regulation of JNK proteins, has been shown to be crucial for neuronal differentiation as well as for neuron function (Coffey, 2014a; Tiwari et al., 2011) .
Interestingly, Tiwari et al. (2011) showed that JNK inhibition results in impaired neuronal differentiation of mouse embryonic stem cells (ESCs). It is therefore conceivable that JIP2 haploinsufficiency also impacts early human neurodevelopment. Supporting this notion, imaging studies of a small group of Phelan-McDermid patients revealed a neurodevelopmental phenotype predominantly effecting the formation of the cerebellum (Aldinger et al., 2013) .
Crucially, such a morphological phenotype has not been observed in Shank3 knockout mice.
Given the complexity of the deletions, we hypothesize that, while a small number of patients lacking only SHANK3 have been diagnosed, 22qDS may frequently not only be the consequence of heterozygous loss of SHANK3 but might additionally be linked to loss of JIP2. In this study we present evidence that both SHANK3 and JIP2 contribute to disease-specific phenotypes that occur at distinct neurodevelopmental stages. Based on these observations we propose a disease mechanism that involves the MAPK pathway and the regulatory function of JNK proteins as well as impaired mTOR pathway activity. We believe that the realization of this complex neurodevelopmental and functional phenotype is crucial for successful development of potential pharmacological interventions.
Results

Patient-specific iPSCs show impaired neuronal maturation.
Patient-specific iPSCs and ESCs were differentiated into NPCs and mature cortical neurons and immunoflourescence and immunoblot analysis was used to characterize basal identities ( Fig.1A-C ). Morphological and molecular profiling revealed that both patient and control PSCs could efficiently generate cortical neurons. Both cell populations sequentially differentiated into cells expressing NPC markers such as PAX6 and NESTIN and continued in vitro maturation resulted in neurons expressing pan-neuronal markers such as TUJ1 and MAP2.
Comparing patient and control neurons, we observed the expected reduction of protein levels for SHANK3 and JIP2 as well as a severe reduction of neuronal markers such as DCX and NeuN (Fig.1C&D ). JNK proteins were only weakly induced in patient neurons as compared to control neurons. Gradual induction of JNK during differentiation of mouse ESCs into neurons has been documented during neural induction (Tiwari et al., 2011) . Strikingly, impaired up-regulation of JIP2 in patient neurons coincided with failed induction of JNK proteins ( Fig.1C&D ). This observation prompted us to investigate electrophysiological properties of mutant cells as an additional criterion for neural maturation. We Comparative raster plots across 64 individual electrodes at day 71 of differentiation clearly showed higher activity for control neurons (Fig.1J ).
Quantification of active electrodes across differentiation experiments comparing
control and patient neurons also revealed reduced over-all activity in 22q13 neurons at later stages ( Fig.1K ). By analyzing the mean spike rate during in vitro maturation we found a gradual increase over time for control neurons (Fig.1L ).
Together with increasing numbers of active electrodes this observation indicates an increase in network activity in the control cultures. During the differentiation time-course spike rates remained low for patient neurons with significant reduction particularly in late stage mutant neurons. Thus, our results indicate severely impaired network activity in patient neurons.
Postsynaptic density proteins establish tightly packed aggregates to facilitate efficient synaptic transmission. Furthermore, these structures are directly linked to intracellular downstream signaling pathways (Suppl. Fig.1A ). Protein analysis in 3 month old neurons confirmed a severe reduction of SHANK3 in the 22qDS mutant cells associated with reduced levels of direct and indirect binding partners of SHANK3 while pan-neuronal markers appear to be unchanged (Suppl. Fig.1B ). In addition, we observed reduced protein levels of AKT and mTOR and their phospho-variants in patient neurons. The AKT/mTOR pathway has recently been associated with Phelan-McDermid Syndrome (Bidinosti et al., 2016) . We also detected reduced levels of Homer and PI3K enhancer (PIKE), which mediate signal transduction to PI3-Kinase and eventually trigger the activation of the mTOR complex (Suppl. Fig.1C ). This result confirms that loss of SHANK3 not only leads to impaired synaptic transmission but also influences central intracellular pathways in mature neurons.
Mutant iPSC-derived neural progenitors reveal a neurodevelopmental phenotype.
Our initial observation that 22qDS neurons show severely impaired in vitro maturation led us to explore whether neurodevelopmental defects might be detectable already earlier during the differentiation process and consequently result in functional differences. For this we genetically engineered fluorescent NPC reporter cell lines for the patient and control background that would allow purification of a defined cell population. We used CRISPR/Cas9 gene targeting to integrate a GFP reporter cassette into the endogenous locus of PAX6, a well characterized NPC marker (Georgala et al., 2011; Osumi et al., 2008 ) (see Fig.2A for targeting strategy). Correctly targeted clones were identified by puromycin selection and Southern Blot assays ( Fig.2B ) and differentiation of these clones into NPCs activated the PAX6-GFP reporter in cells with typical NPC morphology (see representative immuno-staining in Fig.2C ). Clones with CRISPR/Cas9 induced double strand breaks in the second allele (PAX6 GFP/-) resulted in largely GFP negative cell populations upon differentiation and were therefore excluded from further analyses (suppl. Fig.2A&B ). Separation of GFP positive and GFP negative populations by FACS ( Fig.2D and suppl. Fig.2B ) enabled the analysis of global gene expression in a homogenous NPC population. Expression profiling identified a large set of differentially expressed genes comparing the mixed population with the GFP positive and GFP negative fraction ( Fig.2E and suppl. Fig.2C ). More specifically, NPC markers were up-regulated in the GFP positive fraction (Fig.2F ), while genes up-regulated in the GFP negative fraction were identified as neural crest markers (data not shown).
Gene ontology analysis revealed the up-regulated population of genes in the NPC fraction as genes characteristic for forebrain progenitors (strongly enriched GO terms are e.g. telencephalon and forebrain development, axon guidance, neuron differentiation, etc.) (Fig.2G ). This result confirms PAX6 as robust NPC marker that can be used to purify a defined progenitor population. More detailed transcript analysis showed that NPC markers such as NESTIN, MSI1, ASCL1
and several SOX family members were equally expressed in purified control and patient NPCs. (suppl. Fig.2D&E ).
Having identified specific NPC signatures in control and patient Pax6-GFP sorted cells we used this system to compare the expression profiles between purified control and patient NPCs to identify potentially disease relevant differences.
RNA-Seq analysis showed that relative expression levels of genes within the deletion were largely reduced in patient NPCs and fluctuated around a 0.5 fold expression while expression of a set of NPC markers showed a high level of similarity ( Fig.2H and suppl. Fig.2F ). Global gene expression analysis identified a large set of genes (approx. 300) that were differentially expressed in purified patient NPCs (Fig.2I ) and gene ontology analysis classified the down-regulated fraction as genes with biological functions such as 'regulation of neurogenesis', 'regulation of nervous system development' and 'neuron differentiation' (Fig.2 J) .
This result provides evidence that phenotypic changes in 22qDS NPC already occur before mature synapses have been established and underlines the notion that mutations in SHANK3 may not be the sole factor determining the pathology in the majority of Phelan-McDermid syndrome patients.
Isogenic ESC-derived neural cell types recapitulate patient-specific phenotypes.
Comparing different iPSC lines in order to evaluate disease relevant phenotypes can be particularly challenging as heterogeneous genetic backgrounds may drastically mask subtle cellular phenotypes. Recent advances in genome editing, however, have enabled the generation of isogenic mutant lines that are genetically identical except for the disease relevant deletion or mutation (Li et al., 2013; Soldner et al., 2011) . To generate isogenic ESC lines that carry a similar deletion as the patient-specific iPSC line used above we expressed Cas9 protein and deletion-flanking gRNAs in the WIBR#3 hESC line (see Fig.3A for targeting scheme). We obtained clones that carried a heterozygous deletion of approximately 93kb of the long arm of chromosome 22. PCR analysis across or flanking the deletion site identified three heterozygous clones that recapitulated a patient-specific deletion (Fig.3B ). Sequence analysis of the "wild type" allele showed that the 5' targeting site contained only a single base pair deletion upstream of the JIP2 gene (Fig.3C ). This frame shift mutation however did not impact heterozygous expression of JIP2 (Fig.3F&G ). Sequencing of the 3' targeting site on the other hand indicated several INDELs in the isogenic deletion lines (Fig.3C) . We found deletion-specific reduction of SHANK3 particularly affecting individual isoforms in isogenic Δ22 lines (Fig.3F&G ). Differentiation into NPCs appeared to be normal as assessed by immunostaining for NESTIN and PAX6 (Fig.3D&E ). Subsequent differentiation into cortical neurons resulted in equal expression of the pan-neuronal marker TUJ1 in all compared lines (WIBR#3, WIBR#3_Δ22-1, WIBR#3_Δ22-2 and 22q13 iPSCs). Expression of JIP2 and the JIP binding partner JNK 1/3 was, however, reduced in all deletion lines ( Fig.3 F&G) . This result shows that genetically engineered 22qDS lines reliably recapitulate molecular phenotypes as observed in patient-specific cell types. In addition we observed reduced levels of DCX in isogenic ESC-derived neurons (Fig.3F&G) ), confirming the neurodevelopmental molecular phenotype described earlier in iPSC-derived neurons.
Pharmacological activation of the neuropilin 1 receptor recues JNK expression in maturing patient neurons.
Molecular and electrophysiological phenotypes have been described before in the 22qDS mutant cells. However, the contribution of JIP2 haploinsufficiency to 22qDS has not been investigated in human neurons. Maturation of cortical pyramidal neurons depends on robustly established semaphorin signaling which subsequently activates JNK proteins (Calderon de Anda et al., 2012) . Moreover it has been established that JIP and JNK proteins form functional complexes in order to facilitate kinase activities (Koushika, 2008; Kukekov et al., 2006; Mooney and Whitmarsh, 2004) . We therefore hypothesized that JIP2 haploinsufficiency and consequently reduced JNK activity might contribute to impaired neuronal maturation. In order to elucidate potentially underlying molecular pathways we characterized known signaling mediators within the semaphorine pathway.
Semaphorins are secreted guidance cues that bind to neuropilin receptors such as NRP1 (Maden et al., 2012; Pasterkamp, 2012; Tran et al., 2009 ). NRP1 activates the downstream kinase TAOK2 (thousand-and-one amino acid 2 kinase) which in turn phosphorylates and activates JNK proteins and tightly regulated JNK activity is know to be crucial for e.g. neuronal maturation and axon guidance processes (see Fig.4A for semaphorin pathway scheme) (Coffey, 2014b; Koushika, 2008) . RNA-Seq analysis revealed that, while JIP2 is reduced in patient-derived NPCs, expression levels of TOAK2 and JNK1 are similar when comparing control and patient NPC transcript levels. Strikingly, we observed an increase in NRP1 transcript in 22qDS NPCs (Fig.4B) . Except for DCX only minor transcript reductions were found in a set of direct JNK target genes (Fig.4B) .
However, protein analysis in neurons showed a decrease of JIP2, TOAK2, JNK1/3 and cJun (Fig.4C) . These observations are consistent with the possibility that the function of JNK proteins rely on JIP binding particularly in differentiating neurons. In support of this notion we find that pharmacological stimulation of the NRP1 receptor by recombinant SEMA3A a) reverses up-regulation of NRP1 transcripts in patient neurons and restores control levels after 2h of in vitro exposure and b) rescues the expression levels of TOAK2 and JNK but did not stimulate JIP2 expression (Fig.4D ).
Discussion
We used pluripotent stem cells to study molecular and cellular phenotypes in NPCs and cortical neurons of 22qDS patients. Detailed analyses of defined neurodevelopmental stages suggested a novel disease-relevant mechanism that manifests in NPCs and negatively impacts neuronal maturation. Loss of JIP2 may impact expression levels of a large set of neurodevelopmental genes.
Mechanistically this can be linked to impaired JNK complex function, and pharmacological stimulation of the semaphorin pathway rescues JNK expression.
Our study adds mechanistic insight to this complex neurodevelopmental disease beyond SHANK3 haploinsufficiency.
22qDS has recently been connected to impaired synaptic transmission and disrupted intracellular signaling (Bidinosti et al., 2016; Lu et al., 2016; Shcheglovitov et al., 2013; Yi et al., 2016) . Both cellular phenotypes place SHANK3 at the center of the underlying molecular mechanisms. While these findings significantly improve our understanding of this complex disorder it is crucial to note that the vast majority of patients have large chromosomal deletions, which encompass many adjacent genes consistent with mechanistic causes likely being more complex than currently recognized.
Human pluripotent stem cells provide a powerful tool to study such complex disorders, particularly if pathogenic genetic mutations have been identified (Soldner and Jaenisch, 2012; Soldner et al., 2016; Takahashi and Yamanaka, 2013 ). Here we combined human PSC technology and genome editing techniques to further study and dissect disease-relevant mechanisms. We confirmed findings that identified SHANK3 as a crucial contributor to symptoms associated to 22qDS. Loss of SHANK3 impaired intracellular signaling, in particular the AKT/mTOR pathway, and led to reduced synaptic activity in neurons in vitro. Recently, MEA recordings from Shank3 knockout mouse cortical neurons showed a reduction in network activity (Lu et al., 2016) . Our findings in human cortical neurons confirm this observation. However, impairments seen in patient neurons appear to be more pronounced. The more severe cellular phenotype seen in patient-specific neurons maybe be due to contributions of additional genes that are most commonly deleted in 22qDS.
We found that deletion of JIP2 (aka MAPK8IP2 or IB2) likely contributes to an early neurodevelopmental phenotype that can already be detected in neural progenitors. While the role of JIP2 in ASD-type diseases is poorly understood, genetic mouse models support a relevant role of this MAPK pathway-related scaffold protein (Giza et al., 2010) . Moreover, JIP proteins have been identified as direct binding partners of JNK proteins, which are know to be involved in neuronal maturation and proper neuron function (Coffey, 2014b; Koushika, 2008; Mooney and Whitmarsh, 2004; Whitmarsh, 2006) . We found that loss of JIP2 coincided with reduced JNK expression in NPCs and mature neurons and detailed analysis of purified iPSC-derived NPCs identified a large set of neurodevelopmental genes to be misregulated. Previous studies described the pivotal role of JNK proteins during in vitro differentiation of mouse ESCs towards terminally differentiated neurons. JNK complexes specifically bind and activate the promoters of neurodevelopmental genes and inhibition of JNK leads to severely impaired neuronal differentiation, identifying JNK proteins as epigenetic regulators during neuronal maturation (Tiwari et al., 2011) . We hypothesize that loss of JIP2 negatively impacts complex formation with JNK, which consequently contributes to a neurodevelopmental defect. Notably, neuropilin receptor 1 (NRP1), a semaphorin-specific receptor in developing neurons, was found to be up-regulated in patient NPCs and neurons. This specific increase in NRP1 might be a compensatory mechanism in order to maintain activity levels of the semaphorin pathway as needed for properly regulated neuronal maturation.
Conversely, we also found that pharmacological stimulation of NRP1 restored JNK levels in neurons and NRP1 itself returned to control levels. This suggests a regulatory feedback loop in which JNK impacts NRP expression and vice versa.
However, genetically controlled knockout experiments are needed to ascertain this theory. We did not observe significant up-regulation of JIP2 upon NRP1 stimulation. While it is possible that expression of the wild-type allele is increased, a more complex gene regulation may prevent specific induction of JIP2 in patient cells. triggers the activation of the AKT/mTOR pathway as well as the MAPK pathway and is therefore is able to ameliorate some 22qDS phenotypes. Earlier studies have shown that IGF-1 treatment improves cellular and behavioral phenotypes and even disease specific symptoms in patients (Bozdagi et al., 2013; Kolevzon et al., 2014; Shcheglovitov et al., 2013) .
Modeling complex neurological diseases such as 22qDS is challenging and require human disease relevant systems as animal models might not be optimal to understand specific and potentially subtle phenotypes of human disease.
Further investigation is needed to carefully dissect the independent roles of SHANK3 and JIP2. While previous studies focused on iPSC lines from patients that did not present with JIP2 deletions it would be useful to engineer isogenic ESC lines that carry a deletion for either SHANK3 or JIP2. Such a genetically defined approach would provide robust answers regarding the involvement of both candidate genes. Our study adds important insight in the understanding of underlying mechanistic processes in 22qDS and suggests neuropilin receptors as additional therapeutic targets.
Experimental Procedures
IPSC induction and neural differentiation
22qDS patient fibroblasts were acquired from the RUCDR cell repository (http://www.rucdr.org/) and reprogrammed using the Stemgent RNA reprogramming kit (Warren et al., 2010) . Briefly, patient fibroblasts were plated on NuFF feeder cells in varying densities to determine the most efficient reprogramming condition and transfected daily with the reprogramming cocktail for about two weeks (see Stemgent instructions). Clones were picked manually and expanded on inactivated mouse fibroblasts. WIBR3, a human ESC line described previously (Lengner et al., 2010) , was used as control line. All cell lines used and generated are summarized in table 1. For neural induction and cortical neuron differentiation PSCs were exposed to dual SMAD inhibition combined with established optimized protocols for cortical in vitro differentiation (Chambers et al., 2009; Shi et al., 2012a Shi et al., , 2012b . PAX6-GFP reporter lines were differentiated for up to 4 weeks and were subjected to FACS upon up-regulation of GFP. Mature cortical neurons were derived from PSC-derived NPC by extended differentiation in N2/B27 medium for up to 3 month. Differentiation stages were identified by morphological characteristics and cell type specific marker expression.
Electrophysiological characterization of PSC-derived neurons
To analyze electrophysiological properties of maturing neurons we used Axion Multi-Electrode-Arrays (https://www.axionbiosystems.com/). Electrode-containing wells were coated with poly(ethyleneimine) solution (Sigma-Aldrich, P3143) and
Matrigel (VWR, #47743). Approx. 120.000 immature neurons were plated directly on top of the electrode arrays and cells were allowed to settle for 20min after which cells were cultured in 1ml N2B27 medium for up to 3 month. Medium was changed every 2 days. Dependent on the intensity of detected field potentials arrays were measured 2-4 times a week. Data were recorded for 300 sec. per session. Data were acquired using AxIS software and analyzed using NeuroMetrix and Prism GraphPad.
